These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 11449569)

  • 1. Hydrophobicity and functionality maps of farnesyltransferase.
    Ahmed S; Majeux N; Caflisch A
    J Mol Graph Model; 2001; 19(3-4):307-17, 380-7. PubMed ID: 11449569
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The basis for K-Ras4B binding specificity to protein farnesyltransferase revealed by 2 A resolution ternary complex structures.
    Long SB; Casey PJ; Beese LS
    Structure; 2000 Feb; 8(2):209-22. PubMed ID: 10673434
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The crystal structure of human protein farnesyltransferase reveals the basis for inhibition by CaaX tetrapeptides and their mimetics.
    Long SB; Hancock PJ; Kral AM; Hellinga HW; Beese LS
    Proc Natl Acad Sci U S A; 2001 Nov; 98(23):12948-53. PubMed ID: 11687658
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cocrystal structure of protein farnesyltransferase complexed with a farnesyl diphosphate substrate.
    Long SB; Casey PJ; Beese LS
    Biochemistry; 1998 Jul; 37(27):9612-8. PubMed ID: 9657673
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Kinetic studies of protein farnesyltransferase mutants establish active substrate conformation.
    Pickett JS; Bowers KE; Hartman HL; Fu HW; Embry AC; Casey PJ; Fierke CA
    Biochemistry; 2003 Aug; 42(32):9741-8. PubMed ID: 12911316
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Theoretical studies on binding and specificity mechanisms of farnesyltransferase (FTase) and geranylgeranyltransferase type-I (GGTase-I) inhibitors by molecular modeling.
    Zhou S
    Comb Chem High Throughput Screen; 2014; 17(6):509-19. PubMed ID: 24444014
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CA1A2X-competitive inhibitors of farnesyltransferase as anti-cancer agents.
    Omer CA; Kohl NE
    Trends Pharmacol Sci; 1997 Nov; 18(11):437-44. PubMed ID: 9426472
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discovery and structure-activity relationships of novel piperidine inhibitors of farnesyltransferase.
    Nara S; Tanaka R; Eishima J; Hara M; Takahashi Y; Otaki S; Foglesong RJ; Hughes PF; Turkington S; Kanda Y
    J Med Chem; 2003 Jun; 46(12):2467-73. PubMed ID: 12773050
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Design, synthesis and early structure-activity relationship of farnesyltransferase inhibitors which mimic both the peptidic and the prenylic substrate.
    Schlitzer M; Böhm M; Sattler I; Dahse HM
    Bioorg Med Chem; 2000 Aug; 8(8):1991-2006. PubMed ID: 11003144
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Time-dependent inhibition of protein farnesyltransferase by a benzodiazepine peptide mimetic.
    Roskoski R; Ritchie PA
    Biochemistry; 2001 Aug; 40(31):9329-35. PubMed ID: 11478901
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An evolutionary approach for structure-based design of natural and non-natural peptidic ligands.
    Budin N; Ahmed S; Majeux N; Caflisch A
    Comb Chem High Throughput Screen; 2001 Dec; 4(8):661-73. PubMed ID: 11812261
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Farnesyltransferase and geranylgeranyltransferase I: structures, mechanism, inhibitors and molecular modeling.
    Shen M; Pan P; Li Y; Li D; Yu H; Hou T
    Drug Discov Today; 2015 Feb; 20(2):267-76. PubMed ID: 25450772
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Benzimidazolones and indoles as non-thiol farnesyltransferase inhibitors based on tipifarnib scaffold: synthesis and activity.
    Li Q; Li T; Woods KW; Gu WZ; Cohen J; Stoll VS; Galicia T; Hutchins C; Frost D; Rosenberg SH; Sham HL
    Bioorg Med Chem Lett; 2005 Jun; 15(11):2918-22. PubMed ID: 15911281
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Protein farnesyltransferase isoprenoid substrate discrimination is dependent on isoprene double bonds and branched methyl groups.
    Micali E; Chehade KA; Isaacs RJ; Andres DA; Spielmann HP
    Biochemistry; 2001 Oct; 40(41):12254-65. PubMed ID: 11591144
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Design, synthesis, and characterization of piperazinedione-based dual protein inhibitors for both farnesyltransferase and geranylgeranyltransferase-I.
    Qiao Y; Gao J; Qiu Y; Wu L; Guo F; Lo KK; Li D
    Eur J Med Chem; 2011 Jun; 46(6):2264-73. PubMed ID: 21440964
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Protein farnesyltransferase inhibitors.
    Ayral-Kaloustian S; Salaski EJ
    Curr Med Chem; 2002 May; 9(10):1003-32. PubMed ID: 12733981
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Probing the hydrophobic pocket of farnesyltransferase: aromatic substitution of CAAX peptidomimetics leads to highly potent inhibitors.
    Qian Y; Marugan JJ; Fossum RD; Vogt A; Sebti SM; Hamilton AD
    Bioorg Med Chem; 1999 Dec; 7(12):3011-24. PubMed ID: 10658608
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Conversion of protein farnesyltransferase to a geranylgeranyltransferase.
    Terry KL; Casey PJ; Beese LS
    Biochemistry; 2006 Aug; 45(32):9746-55. PubMed ID: 16893176
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Non-thiol farnesyltransferase inhibitors: the concept of benzophenone-based bisubstrate analogue farnesyltransferase inhibitors.
    Schlitzer M; Sattler I
    Eur J Med Chem; 2000; 35(7-8):721-6. PubMed ID: 10960188
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Protein farnesyltransferase-catalyzed isoprenoid transfer to peptide depends on lipid size and shape, not hydrophobicity.
    Subramanian T; Liu S; Troutman JM; Andres DA; Spielmann HP
    Chembiochem; 2008 Nov; 9(17):2872-82. PubMed ID: 18985644
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.